CytomX Therapeutics, Inc. (CTMX)
NASDAQ: CTMX · Real-Time Price · USD
3.370
+0.080 (2.43%)
Aug 25, 2026, 4:00 PM EDT - Market closed
CytomX Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 18.3 | 76.2 | 138.1 | 101.21 | 53.16 | 37.31 | |
Revenue Growth | -87.03% | -44.82% | 36.45% | 90.38% | 42.48% | -45.47% |
Gross Profit | 18.3 | 76.2 | 138.1 | 101.21 | 53.16 | 37.31 |
Selling, General & Admin | 32.08 | 28.74 | 29.73 | 30.02 | 40.45 | 39.16 |
Research & Development | 73.38 | 67.03 | 83.38 | 77.68 | 106.55 | 114.19 |
Operating Expenses | 105.46 | 95.77 | 113.11 | 107.7 | 147 | 153.35 |
Operating Income | -87.15 | -19.56 | 25 | -6.48 | -93.84 | -116.04 |
Interest & Investment Income | 7.72 | 5.21 | 7.14 | 9.84 | 1.68 | 0.26 |
Currency Exchange Gain (Loss) | 0.01 | 0.03 | -0.04 | -0.03 | 0.34 | -0.08 |
EBT Excluding Unusual Items | -79.42 | -14.33 | 32.09 | 3.32 | -91.82 | -115.87 |
Merger & Restructuring Charges | - | -2.8 | - | - | -7.5 | - |
Pretax Income | -79.42 | -17.13 | 32.09 | 3.32 | -99.32 | -115.87 |
Income Tax Expense | 0.23 | 0.24 | 0.22 | 3.89 | - | - |
Net Income | -79.65 | -17.37 | 31.87 | -0.57 | -99.32 | -115.87 |
Preferred Dividends & Other Adjustments | 3 | 3 | - | - | - | - |
Net Income to Common | -82.66 | -20.37 | 31.87 | -0.57 | -99.32 | -115.87 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 183 | 138 | 84 | 74 | 66 | 64 |
Shares Outstanding (Diluted) | 183 | 138 | 85 | 74 | 66 | 64 |
Shares Change | 88.30% | 62.77% | 14.82% | 12.27% | 2.48% | 39.01% |
EPS (Basic) | -0.45 | -0.15 | 0.38 | -0.01 | -1.51 | -1.81 |
EPS (Diluted) | -0.45 | -0.15 | 0.38 | -0.01 | -1.51 | -1.81 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -82.48 | -75.81 | -86.54 | -56.88 | -112.53 | -120.64 |
Free Cash Flow Per Share | -0.45 | -0.55 | -1.02 | -0.77 | -1.71 | -1.88 |
Gross Margin | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
Operating Margin | -476.17% | -25.67% | 18.10% | -6.41% | -176.50% | -311.00% |
Profit Margin | -451.59% | -26.73% | 23.08% | -0.56% | -186.82% | -310.54% |
Free Cash Flow Margin | -450.65% | -99.48% | -62.66% | -56.19% | -211.67% | -323.33% |
EBITDA | -86.21 | -18.19 | 26.76 | -4.31 | -91.39 | -113.34 |
EBITDA Margin | - | -23.87% | 19.38% | -4.26% | -171.91% | - |
D&A For EBITDA | 0.94 | 1.38 | 1.77 | 2.18 | 2.44 | 2.71 |
EBIT | -87.15 | -19.56 | 25 | -6.48 | -93.84 | -116.04 |
EBIT Margin | - | -25.67% | 18.10% | -6.41% | -176.50% | - |
Effective Tax Rate | - | - | 0.70% | 117.12% | - | - |